Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Cantor Fitzgerald cut its price target on GoDaddy Inc. to $90 from $130 and kept a Neutral rating after the company reported a mixed fourth quarter. GoDaddy beat on adjusted EPS and revenue but showed slower bookings growth and issued revenue guidance for Q1 and fiscal 2026 that came in below prior street expectations. Management highlighted progre…
Cantor Fitzgerald reiterated an Overweight rating and a $63.00 price target on Supernus Pharmaceuticals after the company reported stronger-than-expected fiscal 2025 results and provided an update on supply for ONAPGO. Revenue beat, high gross margins and guidance for ONAPGO underpinned the call; Stifel adjusted its target to $55 while keeping a Ho…
Novartis plans to construct a 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the company's fifth RLT site in the United States and its first in the state. Construction is scheduled to begin this year, with the plant expected to be operational in 2028. The investment is part of a previously announced $2…
Driven Brands Holdings Inc. suffered a sharp stock decline after disclosing it will delay filing fiscal 2025 results and must restate financial statements for fiscal years 2023 and 2024. The company and its audit committee identified material errors spanning lease accounting, cash reconciliations, revenue recognition and expense classification, and…
Goldman Sachs cautions that recent AI-related capital spending surprises and growing concern about which firms will benefit from AI are fueling equity market volatility. While near-term earnings have held up, the bank says uncertainty over long-term winners and losers is unlikely to abate soon and could leave segments of the AI infrastructure space…
Cantor Fitzgerald cut its price target on Lucid Group Inc. to $14 from $21 while keeping a Neutral rating, citing a lower production outlook and continued margin deficits. Lucid posted stronger-than-expected revenue and record deliveries in the quarter, but a widening adjusted loss and a production forecast that falls short of consensus prompted th…
Saudi Arabia's stock market closed lower on Wednesday as losses in Media & Publishing, Hotels & Tourism and Building & Construction pushed the Tadawul All Share down 0.54% to a one-month low. Market breadth was negative, with decliners outnumbering advancers and a number of stocks hitting multi-period lows. Oil and gold prices rose alongside a marg…
Cronos Group (CRON) is executing a capital-efficient international expansion - acquiring the Netherlands' market leader and launching premium Lord Jones product in Israel - while showing notably strong liquidity and a compact enterprise value relative to market cap. We view the next 45 trading days as an attractive window to take a tactical long po…
Amazon is trading at roughly $209 and carries a market cap near $2.24 trillion while posting a P/E around 29x, P/S 3.12 and EV/EBITDA ~25x. With AWS Graviton hitting a $10B ARR inflection and smart money increasing exposure, this is an actionable long for the next 46-180 trading days. Entry $206.00, stop $185.00, target $285.00.
H.C. Wainwright trimmed its 12-month price target on Summit Therapeutics (NASDAQ: SMMT) to $30 from $40 while keeping a Buy rating, attributing the reduction to uncertainty over the timing of overall survival data from China trials. The firm raised its discount rate and flagged that the stock's upside this year depends on definitive front-line over…
H.C. Wainwright raised its 12-month price target for ORIC Pharmaceuticals to $25 from $23 and kept a Buy rating, citing an active slate of clinical readouts in 2026 that could shape registrational plans. The company's shares have rallied sharply year-to-date and over the past week, while analysts point to upcoming ORIC-944 dose optimization data an…
H.C. Wainwright reduced its 12-month price target for Corcept Therapeutics to $60 from $67 while retaining a Buy rating, citing a more cautious pricing outlook for the Korlym franchise. The action follows fourth-quarter 2025 results that missed revenue and adjusted EPS expectations, operational disruptions tied to a specialty pharmacy transition, a…
H.C. Wainwright reduced its price target on BioMarin Pharmaceutical to $55 from $60 and kept a Neutral rating, citing increased competitive pressure on the company's VOXZOGO treatment. The stock trades at $62.62, and analysts' targets span $60 to $120. Financial results for the fourth quarter of 2025 were mixed, with EPS missing forecasts but reven…
H.C. Wainwright increased its price target on Apellis Pharmaceuticals to $48 from $45 while keeping a Buy rating, citing a more favorable outlook for Syfovre driven by improving affordability in the geographic atrophy market. The firm raised peak sales estimates to $1 billion and revised near-term revenue expectations, reflecting stronger momentum …
H.C. Wainwright cut its price target on Day One Biopharmaceuticals to $22 from $25 but left its Buy rating intact. The biotech, valued at $1.23 billion, posted strong commercial performance for OJEMDA in 2025 and reiterated 2026 revenue guidance as it progresses a pipeline of antibody-drug conjugates with data and enrollment milestones expected thr…
H.C. Wainwright increased its price target for Alpha Tau Medical Ltd. to $12.00 from $9.00 while keeping a Buy rating, after Japan's Ministry of Health, Labour and Welfare approved Alpha DaRT for certain head and neck cancers. The approval triggers a required post-market surveillance study in Japan and opens reimbursement and clinical discussions w…
Switzerland's Federal Council has approved a one-off payment of 50,000 Swiss francs ($56,000) to severely injured survivors and families of those who died in the New Year bar fire at Crans-Montana. The measure, described as a 'solidarity contribution,' is intended to deliver rapid financial relief, and the government will also fund mediation effort…
Jefferies upgraded Enphase Energy to Buy from Hold and raised its price target to $57 from $42, pointing to improving demand and margin clarity after a projected 2026 volume trough. The firm highlighted growing financing confidence, a commercial ramp of the IQ9 platform, and upcoming fifth-generation storage hardware in H2 2026 as key drivers. Mult…
J.P. Morgan placed FinecoBank Banca Fineco SpA on Positive Catalyst Watch ahead of the bank's inaugural Capital Markets Day on March 4, raising its December 2027 price target to €27 from €26.40 and keeping an overweight rating. The bank expects management to disclose above-consensus growth targets for 2026-29 that could lift earnings-per-share esti…
UBS analyst Matthew Mish set out a tail-risk scenario in which a rapid, severe AI disruption would materially worsen defaults and tighten credit across U.S. high-yield, leveraged loan and private credit markets. The bank quantified potential default rates, estimated losses and drawn exposures, and highlighted concentrations and stress signals that …
In its annual budget, South Africa's National Treasury said it will propose a "principles-led" fiscal anchor at the mid-term budget later this year, prioritizing a guideline-based framework rather than a fixed numerical target to shore up public finances amid a steep rise in debt and modest growth projections.
Futures tied to Canada’s primary equity benchmark rose modestly on Wednesday as investors positioned ahead of Nvidia’s earnings. The S&P/TSX 60 futures gained 8 points, while the prior session saw the S&P/TSX composite reach 33,970.38. Strength in materials and mixed corporate results in Canada and the U.S., plus developments on tariffs and energy …
Shares of Lithium Americas (LAC) and Albemarle (ALB) climbed after Zimbabwe announced an immediate suspension of lithium concentrate and raw mineral exports. The ban will stay in force until mining companies meet government requirements to build processing capacity inside Zimbabwe, accelerating an earlier plan to end concentrate exports by 2027. SQ…
Leerink Partners raised its price target on Vaxcyte to $82 from $77 and kept an Outperform rating after the company reported fourth-quarter 2025 results and said it will resume development of VAX-A1, a Group A Streptococcus vaccine candidate, advancing it into a Phase 1 adult trial in 2026. Vaxcyte has strengthened its balance sheet through recent …
Leerink Partners trimmed its price objective on Tectonic Therapeutics Inc. (NASDAQ: TECX) to $60 from $69 while retaining an Outperform recommendation. The revision follows adjustments in the firm’s discounted cash flow model that reduced the likelihood of success for TX45 and raised the probability for TX2100. Wall Street consensus remains constru…
